Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Recent & Breaking News (NDAQ:ARQT)

Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis

GlobeNewswire November 2, 2020

Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences

GlobeNewswire October 29, 2020

Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

GlobeNewswire October 26, 2020

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

GlobeNewswire October 6, 2020

Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock

GlobeNewswire October 1, 2020

Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

GlobeNewswire September 29, 2020

Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

GlobeNewswire September 29, 2020

Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

GlobeNewswire September 16, 2020

Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020

GlobeNewswire September 15, 2020

Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA

GlobeNewswire September 8, 2020

Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire August 11, 2020

Arcutis to Present at the Wedbush PacGrow Healthcare Conference

GlobeNewswire August 10, 2020

Bethany Dudek Joins Arcutis as Vice President of Quality

GlobeNewswire August 4, 2020

The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis' ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

GlobeNewswire August 3, 2020

Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

GlobeNewswire July 31, 2020

Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer

GlobeNewswire July 27, 2020

Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis

GlobeNewswire July 20, 2020

The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis' ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

GlobeNewswire July 15, 2020

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

GlobeNewswire July 13, 2020

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

GlobeNewswire June 22, 2020